Background and aims
===================

As an important class of heterocyclic compounds, thiazoles are associated with many types of biological properties, including antitumor, antibacterial, antifungal, antitubercular and anti-inflammatory effects \[[@b1-cm-88-521]--[@b3-cm-88-521]\]. Similarly, 1,3,4-oxadiazoline is a versatile lead molecule for the design of bioactive agents. Compounds containing the 1,3,4-oxadiazoline system have been reported to exhibit various biological activities such as anticancer \[[@b4-cm-88-521],[@b5-cm-88-521]\], antibacterial, antifungal, anticonvulsant and anti-inflammatory \[[@b6-cm-88-521]--[@b8-cm-88-521]\]. Moreover, the association of the thiazole system and the oxadiazoline backbone in the same molecule may show antimicrobial synergistic effect.

Considering the biological significance of thiazole and 1,3,4-oxadiazoline derivatives we decided to design a series of thiazolyl-oxadiazolines.

The hydrophilic-lipophilic balance of a substance is a fundamental physical property that plays a pivotal role in the absorption, distribution, metabolism and elimination (ADME) of therapeutic drugs. For the determination of the lipophilicity of biologically active compounds, chromatographic techniques are chosen because the behavior and interaction between molecules in chromatographic and biological systems are very similar. Most molecules cross the cell membranes by passive diffusion; they should be lipophilic enough in order to disseminate through the biological membranes, but also hydrophilic enough to penetrate the cytoplasm. The biological activity of the molecules can be associated with the lipophilic character by retention parameters, which can describe or predict the properties of the active substance. These are either calculated by theoretical methods or are experimentally determined (reverse phase-thin layer chromatography) and help us establish the quantitative structure-retention relationship (QSRR). Furthermore, they express the interaction between the cell membranes and the analyzed molecules \[[@b9-cm-88-521]--[@b13-cm-88-521]\].

This prompted us to study the physicochemical properties of this kind of compounds in detail. Herein, we report the synthesis, the study of lipophilicity and the evaluation of the antimicrobial potential of novel 1,3,4-oxadiazolines containing a thiazole ring in their structure, in the hope to provide a deeper insight into the differences in biological activity between them and to suggest synthesis of new active derivatives.

Materials and methods
=====================

Chemistry
---------

Solvents and reagents used for synthesis and purification were purchased from Alfa Aesar (Karlsruhe, Germany). All chemicals were of analytical grade. The purity of the synthesized compounds was verified by thin layer chromatography and was carried out on precoated Silica Gel 60F254 sheets using heptan -- ethyl-acetate 3:7 as developer and UV absorption for visualization. The melting points were established using an Electrothermal melting point meter and are uncorrected. LC-MS analyses were performed with an Agilent 1100 series and an Agilent Ion Trap SL mass spectrometer. ^1^H-NMR was performed on a Bruker Avance NMR spectrometer operating at 500 MHz, in DMSO-d6 as solvent. Chemical shift values were reported relative to tetramethylsilane (TMS) as internal standard. The synthesis of the compounds **1, 2** and **3** was previously reported \[[@b14-cm-88-521]\]. The chemical structures of compounds ***6a--f, 7a--d*** are presented in [Table I](#tI-cm-88-521){ref-type="table"}, [II](#tII-cm-88-521){ref-type="table"}. Ten compounds with new structures were synthesized ([Figure 1](#f1-cm-88-521){ref-type="fig"}) and characterized.

### General procedure for the synthesis of thiazole-5yl-hydrazide-hydrazones (**4a--d, 5a--b**). \[[@b14-cm-88-521]--[@b16-cm-88-521]\]

To a solution of 2 mmol ***3*** in 5 ml ethanol and a catalytic amount of glacial acetic acid, an equimolar quantity of aldehyde/ketone was added. The reaction mixture was heated under reflux for 3 h. After cooling, the product was filtered off and washed with water.

### General procedure for the synthesis of the thiazolyl-oxadiazolines (**6a--f, 7a--d).** \[[@b14-cm-88-521]--[@b16-cm-88-521]\]

A mixture of hydrazide-hydrazone ***4 a-d and 5 a--b*** (1 mmol) and propionic/acetic anhydride (6 ml) was heated under reflux for 6 h. After cooling the reaction mixture was poured into ice cold water. The separated product was filtered, washed with water, dried and recrystallized from ethanol.

Lipophilicity evaluation
------------------------

The synthesized oxadiazolines were subjected to RP-TLC in order to obtain the parameters that are necessary for the estimation of their lipophilic properties.

The chromatographic behavior of the compounds was studied by using standard chromatographic plates Silicagel 60 RP-180F~254~S (20×20 cm), with a chemically bound C~18~ stationary phase, purchased from Merk (Darmstadt, Germany). Test compounds were dissolved in DMSO to achieve a concentration of 1 mg/ml. These were manually applied as spots at 10 mm from the base and 5 mm from the edges of the plate. The distance between successive spots was 10 mm. The solutions of the investigated compounds were applied using 1 μl standardized chromatographic micropipettes. The mobile phase consisted of a mixture of water and *i*-propanol. Concentrations of *i*-propanol in different proportions, between 60% to 80% with 5% increments, were used. The migration distance of the eluent was 85 mm, in all cases. Before the development, the chamber was saturated with the mobile phase for 15 min. The plates were visually inspected under the UV light (364 nm), each zone was clearly marked, its distance was manually measured and was used to calculate the R~f~ values.

RP-TLC provides retention data in the form of R~f~ (1) and corresponding R~M~ (2) values that can be used to derive chromatographic descriptors for the estimation of lipophilicity: R~M0~, b and PCA \[[@b17-cm-88-521],[@b18-cm-88-521]\].
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1.  R~M0~=lipophilicity estimation parameter

2.  R~M~ = retention of a solute

3.  b = slope

4.  c = concentration of the organic mobile phase modifier (*i*-propanol)

The lipophilic properties of the investigated compounds were evaluated by using the principal component analysis method (PCA, XL-STAT) \[[@b19-cm-88-521]\]. For a better interpretation of the results, these were correlated with cLogP values of the compounds, which were generated by the ChemBioDraw 11.0 software.

Antimicrobial Activity
----------------------

The newly synthesized compounds were screened for their *in vitro* antimicrobial activities against four strains of bacteria (*Staphylococcus aureus* ATCC 49444, *Escherichia coli ATCC 25922, Salmonella typhimurium* ATCC 14028, *Pseudomonas aeruginosa* ATCC 27853) and one strain of fungi (*Candida albicans* ATCC 10231), by the disk diffusion method, according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI, 2012) \[[@b20-cm-88-521]\]. For the antibacterial assay, Mueller-Hinton agar medium (Oxoid, Basingstoke, UK) was used and for the antifungal assay, *YPD agar (Sigma-Aldrich, Germany)* was used. The solutions of the tested compounds were prepared by dissolving each compound in DMSO in order to obtain a concentration of 10 mg/ml. Sterile filter paper disks (6 mm in diameter), impregnated with the solution in DMSO of the test compounds (25μL solution), were placed on the Petri plates, previously seeded "in layer" with the tested bacterial strain inoculums. Gentamicin (25 μL/disk at concentration of 4 μg/mL) was used as positive control for bacteria. Fluconazole (25 μL/disk disk at concentration of 10 mg/mL) was used as positive control for *Candida albicans* ATCC 10231. A paper disk impregnated with DMSO (25μL/disk) was used as a negative control. The plates that were inoculated with bacteria were incubated for 24 h at 37°C and those inoculated with fungal culture were incubated for 24h at 30°C. The inhibition zone diameters were measured in millimeters. All the tests were performed in duplicate and the average was taken as final reading.

Results
=======

Chemistry
---------

The structures of the newly synthesized compounds were correlated with the data obtained from ^1^H NMR and mass spectrometry, given below.

### N′-(4-hydroxy-3-methoxybenzylidene)-2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide **(4a)**

C~20~H~16~F~3~N~3~O~3~S (435,42). Yellow powder. Yield 95%. M.p.: 284°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.29 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.92 (d, 1H, Ph), 7.8 (s, 1H), 7.78 (t, 1H, Ph), 7.44 (s, 1H, Ph), 7.4 ( s, 1H, NH), 7.20 (d, 1H, Ph), 7.07 (d, 1H, Ph), 5.17 (s, 1H, OH), 3.81 ( s, 3H, OCH~3~), 2.73 (s, 3H, CH~3~ thiazole). MS *m/z(%):* 436.8 (M+1, 100).

### N′-(3-ethoxy-4-hydroxybenzylidene)-2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide **(4b)**

C~21~H~18~F~3~N~3~O~3~S (449,45). Yellow powder. Yield 95%. M.p.: 266°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.32 (d, 1H, Ph), 8.28 (s, 1H, Ph), 7.94 (d, 1H, Ph), 7.85 (s, 1H), 7.77 (t, 1H, Ph), 7.44 (s, 1H, Ph), 7.20 (d, 1H, Ph), 7.07 (d, 1H, Ph), 7.01 (s, 1H, NH), 5.20 (s, 1H, OH), 3.6 ( d, 2H, OCH~2~CH~3~), 2.73 (s, 3H, CH~3~ thiazole), 2.5 (t, 3H, ~-~OCH~2~CH~3~). MS *m/z(%):* 450.8 (M+1, 100).

### N′-(4-bromobenzylidene) -2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide **(4c)**

C~19~H~13~BrF~3~N~3~OS (468.29). White powder. Yield 90%. M.p.: 273°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.33 (d, 1H, Ph), 8.25 (s, 1H, Ph), 7.93 (d, 1H, Ph), 7.8 (s, 1H), 7.78 (t, 1H, Ph), 7.37 (d, 1H, Ph), 7.35 (d, 1H, Ph), 7.20 (d, 1H, Ph), 7.17 (d, 1H, Ph), 7.05 (s, 1H, NH), 2.7 (s, 3H, CH~3~ thiazole). MS *m/z(%):* 469.4 (M+1, 100).

### N′-(2,4-dichlorobenzylidene)-2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide **(4d)**

C~19~H~12~Cl~2~F~3~N~3~OS (458.28). White powder. Yield 93%. M.p.: 278°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.33 (d, 1H, Ph), 8.25 (s, 1H, Ph), 7.95 (d, 1H, Ph), 7.81 (s, 1H), 7,79 (t, 1H, Ph), 7.75 (d, 1H, Ph), 7.54 ( s, 1H, NH), 7.44 (s, 1H, Ph), 7.2 (d, 1H, Ph), 2.73 (s, 3H, CH~3~ thiazole). MS *m/z(%):* 459.3 (M+1, 100).

### N′-cyclopentylidene-2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide **(5a)**

C~17~H~16~F~3~N~3~OS (367,39). White powder. Yield 80%. M.p.: 223°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.27 (s, 1H, Ph), 8.26 (d, 1H, Ph), 7.92 (d, 1H, Ph), 7.77 (t, 1H, Ph), 7.1 (s, 1H, NH), 2.7 (s, 3H, CH~3~ thiazole), 2.35-1.3 (m, 8H, cyclopentane). MS *m/z(%):* 368.8 (M+1, 100).

### (N′-cyclohexylidene-2-(3-(trifluoromethyl)phenyl)-4-methylthiazole-5-carbohydrazide) (**5b)**

C~18~H~18~F~3~N~3~OS (381.42). White powder. Yield 90%. M.p.: 244°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.27 (d, 1H, Ph), 8.24 (s, 1H, Ph), 7.91 (d, 1H, Ph), 7.77 (t, 1H, Ph), 6.9 (s, 1H, NH), 2.7 (s, 3H, CH~3~ thiazole), 2.4-1.4 (m, 10H, cyclohexane). MS *m/z(%):* 382.5 (M+1, 100).

### 4-(3-acetyl-5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)-2-methoxyphenyl acetate (**6a**)

C~24~H~20~F~3~N~3~O~5~S (519,49). Yellow powder. Yield 60%. M.p.: 135°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.29 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.92 (d, 1H, Ph), 7.78 (t, 1H, Ph), 7.28 (s, 1H, Ph), 7.21 (s, 1H), 7.17 (d, 1H, Ph), 7.08 (d, 1H, Ph), 3.81 ( s, 3H, ~-~OCH~3~), 2.73 (s, 3H, CH~3~ thiazole), 2.289 (s, 3H, COCH~3~), 2.27 (s, 3H, OCOCH~3~). MS *m/z(%)*: 520.5 (M+1, 100), 478.7 (M+1-COCH~3~, 33.4).

### 4-(3-acetyl-5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-2,3-dihydro-1,3,4-oxadiazol-2-yl)-2-ethoxyphenyl acetate (**6b**)

C~25~H~22~F~3~N~3~O~5~S (533,12). Yellow powder. Yield 65%. M.p.: 140°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm): δ, 8.28 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.92 (d, 1H, Ph), 7.78 (t, 1H, Ph), 7.20 (s, 1H, Ph), 7.20 (s, 1H), 7.17 (d, 1H, Ph), 7.07 (d, 1H, Ph), 4.07 (d, 2H, -CH~2-~CH~3~), 2.728 (s, 3H, CH~3~ thiazole), 2.28 (s, 3H, COCH~3~), 2.27 (s, 3H, OCOCH~3~), 1.29 (t, 3H, -CH~2-~CH~3~). MS *m/z(%):* 534.3 (M+1, 100), 492.3 (M+1-COCH~3~, 47.5).

### 2-methoxy-4-(5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-3-propionyl-2,3-dihydro-1,3,4-oxadiazol-2-yl)phenyl propionate (**6c**)

C~26~H~24~F~3~N~3~O~5~S (547.55). Yellow powder. Yield 60%. M.p.: 136°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.28 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.92 (d, 1H, Ph), 7.78 (t, 1H, Ph), 7.27 (s, 1H, Ph), 7.20 (s, 1H), 7.17 (d, 1H, Ph), 7.07 (d, 1H, Ph), 3.80 ( s, 3H, ~-~OCH~3~), 2.72 (s, 3H, CH~3~ thiazole), 2.7 (d, 2H, OCOCH~2~CH3), 2.6 (d, 2H, COCH~2~CH~3~), 1.13 (t, 3H, OCOCH~2~CH3), 1.1 (t, 3H, COCH~2~CH~3~). MS: *m/z(%):* 548.7 (M+1, 100), 492.7 (M+1-COC~2~H~5,~ 17.39).

### 2-ethoxy-4-(5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-3-propionyl-2,3-dihydro-1,3,4-oxadiazol-2-yl)phenyl propionate (**6d**)

C~27~H~26~F~3~N~3~O~5~S (561,57). Yellow powder. Yield 50%. M.p.: 142°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.28 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.91 (d, 1H, Ph), 7.77 (t, 1H, Ph), 7.25 (s, 1H), 7.19 (s, 1H, Ph), 7.17 (d, 1H, Ph), 7.06 (d, 1H, Ph), 4.065 (d, 2H, -OCH~2-~CH~3~), 2.72 (s, 3H, CH~3~ thiazole), 2.67 (d, 2H, COCH~2~CH~3~), 2.59 (d, 2H, OCOCH~2~CH~3~), 1.28 (t, 3H, -OCH~2-~CH~3~), 1.15 (t, 3H, COCH~2~CH~3~), 1.087 (t, 3H, OCOCH~2~CH~3~). MS *m/z(%):* 563.2 (M+1, 100), 506.4 (M+1-COC~2~H~5~, 45.32).

### 1-(2-(4-bromophenyl)-5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-3(2H)-yl)propan-1-one (**6e**)

C~22~H~17~BrF~3~N~3~O~2~S (524,35). Yellow powder. Yield 70%. M.p.: 155 °C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.27 (d, 1H, Ph), 8.26 (s, 1H, Ph), 7.91 (d, 1H, Ph), 7.77 (t, 1H, Ph), 7.68 (d, 1H, Ph), 7.66 (s, 1H), 7.47 (d, 1H, Ph), 7.47 (d, 1H, Ph), 7.20 (d, 1H, Ph), 2.67 (s, 3H, CH~3~ thiazole), 2.50 (d, 2H, COCH~2-~CH~3~), 1.06 (t, 3H, COCH~2~CH~3~). MS *m/z(%):* 525.8 (M+1, 100).

### 1-(2-(2,4-dichlorophenyl)-5-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-1,3,4-oxadiazol-3(2H)-yl)propan-1-one (**6f**)

C~22~H~16~Cl~2~F~3~N~3~O~2~S (514,35). Yellow powder. Yield 55% .M.p.: 182°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.29 (d, 1H, Ph), 8.27 (s, 1H, Ph), 7.92 (d, 1H, Ph), 7.79 (d, 1H, Ph), 7.78 (t, 1H, Ph), 7.55 (s, 1H, Ph), 7.55 (d, 1H, Ph), 7.35 (s, 1H), 2.7 (s, 3H, CH~3~ thiazole), 2.68 (d, 2H, COCH~2-~CH~3~), 1.08 (t, 3H, COCH~2~CH~3~). MS *m/z(%):* 515.3 (M+1, 100).

### 1-(3-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-4-oxa-1,2-diazaspiro\[4.4\]non-2-en-1-yl)ethanone (**7a**)

C~19~H~18~F~3~N~3~O~2~S (409,43). Yellow powder. Yield 60%. M.p.: 144°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, Yellow powder. Yield 65%. M.p: 143°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.29 (s, 1H, Ph), 8.27 (d, 1H, Ph), 7.91 (d, 1H, Ph), 7.77 (t, 1H, Ph), 2.69 (s, 3H, CH~3~ thiazole), 2.22 (s, 3H, COCH~3~), 2.51-1.77 (m, 8H, cyclopentane). MS *m/z(%):* 410.6 (M+1, 100).

### 1-(3-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-4-oxa-1,2-diazaspiro\[4.5\]dec-2-en-1-yl)ethanone (**7b**)

C~20~H~20~F~3~N~3~O~2~S (423,45). Yellow powder. Yield 65%. M.p.: 143°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.28 (d, 1H, Ph), 8.26 (s, 1H, Ph), 7.91 (d, 1H, Ph), 7.77 (t, 1H, Ph), 2.7 (s, 3H, CH~3~ thiazole), 2.18 (s, 3H, COCH~3~), 1.87-1.03 (m, 10H, cyclohexane). MS *m/z(%):* 424.2 (M+1, 100).

### 1-(3-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-4-oxa-1,2-diazaspiro\[4.4\]non-2-en-1-yl)propan-1-one (**7c**)

C~20~H~20~F~3~N~3~O~2~S (423,45). Yellow powder. Yield 60%. M.p.: 113°C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.3 (s, 1H, Ph), 8.28 (d, 1H, Ph), 7.92 (d, 1H, Ph), 7.78 (t, 1H, Ph), 2.69 (s, 3H, CH~3~ thiazole), 2.69 (t, 3H, COCH~2~CH~3~), 2.61 (d, 2H, COCH~2~CH~3~), 1.98-1.06 (m, 8H, cyclopentane). MS *m/z(%)*: 424.6 (M+1, 100).

### 1-(3-(-2-(3-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)-4-oxa-1,2-diazaspiro\[4.5\]dec-2-en-1-yl)propan-1-one (**7d**)

C~21~H~22~F~3~N~3~O~2~S (437,48). Yellow powder. Yield 50%. M.p.: 144 °C. ^1^H NMR (DMSO-d6, 500 MHz, ppm) δ, 8.28 (d, 1H, Ph), 8.23 (s, 1H, Ph), 7.90 (d, 1H, Ph), 7.77 (t, 1H, Ph), 2.7 (s, 3H, CH~3~ thiazole), 2.6 (d, 2H, COCH~2~CH~3~), 2.5 (t, 3H, COCH~2~CH~3~), 1.91-1.03 (m, 10H, cyclohexane). MS *m/z(%):* 438 (M+1, 100).

Lipophilicity evaluation
------------------------

The R~f~ and R~M~ values, as well as the results of the regression analysis of compounds ***6a--f*** and ***7a--d***, are shown in [Table III](#tIII-cm-88-521){ref-type="table"} and [V](#tV-cm-88-521){ref-type="table"}.

[Table IV](#tIV-cm-88-521){ref-type="table"} contains the eigenvalues of the covariance matrix, disposed from largest to smallest; the third column of this table displays the difference between each eigenvalue and the next smaller eigenvalue and the fourth column shows the proportion.

For a correct assessment of the initial data set, the first two principal components were retained; this explains 99.812% of the total information of the initial data. The first component (PC~1~) explains 98.504% of the total variance and the second 1.308%.

The 2-D scatterplot of the scores corresponding to the first two principal components was generated by the graphic representation of PC~2~=f(PC~1~) ([Figure 2](#f2-cm-88-521){ref-type="fig"}).

For a better interpretation of the lipophilicity parameters PC~1~ and R~M0~, cLogP values were generated ([Table VI](#tVI-cm-88-521){ref-type="table"}).

The variations of cLogP, R~M0~ and PC~1~ values in the five mobile phases are represented in [Figure 3](#f3-cm-88-521){ref-type="fig"}.

While compounds **6f, 6e, 7d, 6d, 7b** and **7c** exhibited high values of the lipophilicity parameters, compounds **7a, 6b, 6c** and **6a** had lower values.

Antimicrobial Activity
----------------------

The thiazolyl-1,3,4-oxadiazolines were screened for their antimicrobial activities against one Gram-positive (*Staphylococcus aureus* ATCC 49444) and three Gram-negative (*Escherichia coli ATCC 25922, Salmonella typhimurium* ATCC 14028 and *Pseudomonas aeruginosa* ATCC 27853) bacterial strains. The antifungal activity was tested against a strain of *Candida albicans* ATCC 10231. The results of the antimicrobial evaluation are summarized in [Table VII](#tVII-cm-88-521){ref-type="table"}.

Discussion
==========

After the structural validation by ^1^H-NMR and mass spectrometry of the newly synthesized thiazolyl-oxadiazolines, we determined their lipophilicity. The linear dependency between the values of R~M0~ (lipophilic parameter) and the values of b (specific hydrophobic surface) show that the thiazolyl-1,3,4-oxadiazolines form a particular series of compounds. The values of the R^2^ parameter showed the linear dependency between the R~M~ parameter and the concentrations of the organic component of the mobile phase ([Table V](#tV-cm-88-521){ref-type="table"}). This interconnection showed us that the chromatographic experiments were appropriately conducted and, moreover, it helped us to assert that we could estimate the lipophilic character of the studied compounds by analyzing the R~M0~ parameter~.~ High values of the R~M0~ parameter indicate a high lipophilicity.

As it can be seen from the data provided in [Table V](#tV-cm-88-521){ref-type="table"}, the first principal component (PC~1~) can replace the R~M0~ parameter for the estimation of the lipophilicity. By using the values of the two principal components, a relative lipophilic scale was created ([Figure 2](#f2-cm-88-521){ref-type="fig"}). A compound with a high lipophilicity is characterized by a low value of the PC~1~ parameter.

By the graphic representation of PC~2~=f(PC~1~) ([Figure 2](#f2-cm-88-521){ref-type="fig"}), this made possible the repartition of the studied compounds into two congeneric series.

-   Class 1: 6a, 6b, 6c, 6d

-   Class 2: 6e, 6f, 7a, 7b, 7c, 7d

A good linear correlation was obtained between the lipophilicity evaluated by RP-TLC and cLogP values (partition coefficient) that were theoretically determined ([Table VI](#tVI-cm-88-521){ref-type="table"}). A high lipophilicity is characterized by high cLogP and R~M0~ values and by low PC1 values. The R~M0~, PC~1~ and cLogP profiles could be well correlated ([Figure 3](#f3-cm-88-521){ref-type="fig"}).

The results obtained revealed that the presence of halogen atoms, with a high atomic volume, on the phenyl ring situated in position 5 of the oxadiazoline system and also of non-polar substituents (cyclopentyl, cyclohexyl), raised lipophilicity. Meanwhile, the substitution of the same phenyl ring with polar groups (-OCH~3~, -OC~2~H~5~) led to lower values of the lipophilicity parameters.

Unfortunately, a correlation between the values of the lipophilic parameters and the antimicrobial activity could not be established, given that the inhibition zone was modest. This correlation between lipophilicity and antibacterial activity does not rule out the importance of the existence of other structural factors involved in the activity.

Conclusions
===========

In this paper, we have presented the synthesis of ten new thiazolyl-oxadiazolines, whose structures were confirmed by ^1^H-NMR and mass spectrometry. We evaluated the lipophilicity of the newly synthesized compounds by RP-TLC using the PCA method. The therapeutic potential was investigated by screening their antimicrobial activity, but the activity was low and could not be correlated with the lipophilicity of the compounds.

This paper was published under the frame of European Social Found, Human Resources Development Operational Programme 2007--2013, project no. POSDRU/159/1.5/136893.
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###### 

The chemical structures of **6a--f.**

  Compound   R       Ar
  ---------- ------- ----
  6a         -CH3    
  6b                 
  6c         -C2H5   
  6d                 
  6e                 
  6f                 

###### 

The chemical structures of **7a--7d.**

  Compound   R           R~1~+R~2~
  ---------- ----------- -----------
  **7a**     -CH~3~      
  **7b**                 
  **7c**     -C~2~H~5~   
  **7d**                 

###### 

R~f~ and R~M~ values for compounds **6a--f, 7a--d.**

  Compound   *i*-PROPANOL : WATER (v:v %)                                                                     
  ---------- ------------------------------ ------- ------- ------- ------- -------- ------- -------- ------- --------
  **6a**     0.323                          0.321   0.420   0.140   0.508   −0.013   0.594   −0.165   0.680   −0.327
  **6b**     0.270                          0.431   0.366   0.238   0.461   0.067    0.552   −0.090   0.639   −0.247
  **6c**     0.211                          0.572   0.295   0.378   0.384   0.205    0.488   0.020    0.616   −0.205
  **6d**     0.164                          0.707   0.236   0.510   0.343   0.282    0.458   0.073    0.575   −0.131
  **6e**     0.100                          0.954   0.165   0.704   0.235   0.512    0.335   0.297    0.447   0.092
  **6f**     0.082                          1.049   0.142   0.781   0.200   0.602    0.300   0.367    0.411   0.156
  **7a**     0.156                          0.733   0.241   0.498   0.307   0.353    0.411   0.156    0.511   −0.019
  **7b**     0.145                          0.770   0.229   0.527   0.282   0.405    0.394   0.186    0.482   0.031
  **7c**     0.117                          0.877   0.200   0.602   0.260   0.454    0.364   0.242    0.465   0.060
  **7d**     0.104                          0.935   0.176   0.670   0.236   0.510    0.335   0.297    0.441   0.102

###### 

The eigenvalues and the ratios of the variance explained by the five components using a covariance matrix: results of PCA.

  Component   Eigenvalue   Difference   Proportion%   Cumulative%
  ----------- ------------ ------------ ------------- -------------
  1           4.925        4.86         **98.504**    98.504
  2           0.065        0.015        **1.308**     **99.812**
  3           0.005        0.002        0.110         99.921
  4           0.003        0.002        0.051         99.972
  5           0.001                     0.028         100

###### 

Regression data and scores on the first two principal components for compounds **6a--f, 7a--d.**

  Compound   R~M0~   b        Linear correlation coefficient (R^2^)   PC~1~    PC~2~
  ---------- ------- -------- --------------------------------------- -------- --------
  **6a**     0.471   −0.160   0.999                                   4.450    −0.262
  **6b**     0.586   −0.168   0.998                                   3.167    −0.054
  **6c**     0.768   −0.191   0.997                                   1.590    0.378
  **6d**     0.922   −0.211   0.999                                   0.408    0.610
  **6e**     1.151   −0.213   0.998                                   −2.197   0.046
  **6f**     1.250   −0.219   0.997                                   −2.971   −0.096
  **7a**     0.898   −0.184   0.995                                   −0.361   −0.028
  **7b**     0.930   −0.181   0.991                                   −0.855   −0.175
  **7c**     1.045   −0.199   0.991                                   −1.537   −0.043
  **7d**     1.114   −0.203   0.995                                   −2.138   −0.095

###### 

cLogP values for compunds **6a--f, 7a--d.**

  Compound   cLogP
  ---------- -------
  **6a**     4.163
  **6b**     4.692
  **6c**     4.54
  **6d**     5.75
  **6e**     6.467
  **6f**     7.03
  **7a**     4.75
  **7b**     5.308
  **7c**     5.278
  **7d**     5.837

###### 

Antimicrobial activity of thiazolyl-1,3,4 oxadiazolines against bacterial and fungal species tested by disc diffusion assay.

                Inhibition Zone (mm)                                    
  ------------- ---------------------- ---------- ---------- ---------- ----------
  6a            7.8±0.4                7.8±0.4    7.3±0.4    6.0±0.0    7.3±0.4
  6b            7.3±0.4                7.3±0.4    7.5±0.7    6.3±0.4    7.5±0.7
  6c            8.1±0.1                8.0±0.0    8.0±0.0    7.3±0.4    8.0±0.0
  6d            8.3±0.4                7.0±0.0    9.3±0.4    7.8±0.4    7.3±0.4
  6e            8.0±0.0                8.5±0.0    9.5±0.7    6.8±0.4    8.0±0.0
  6f            \-                     \-         \-         7.3±0.4    6.0±0.0
  7a            9.0±0.0                9.3±0.4    8.0±0.0    6.8±0.4    7.0±0.0
  7b            8.1±0.1                8.3±0.4    7.3±0.4    6.0±0.0    6.8±0.4
  7c            7.8±0.4                8.3±0.4    6.3±0.4    6.0±0.0    6.3±0.4
  7d            8.8±0.4                8.8±0.4    8.8±0.4    6.8±0.4    7.8±0.4
  Gentamicin    18.8±0.4               25.3±0.4   20.0±1.4   13.8±0.4   NT
  DMSO          \-                                \-         \-         \-
  Fluconazole   NT                     NT         NT         NT         21.5±0.7

Each value is the mean ± SD of two independent measurements

NT- Not Tested
